A Squalene-Based Nanoemulsion for Therapeutic Delivery of Resiquimod
Agonists for toll-like receptors (TLRs) have shown promising activities against cancer. In the present study, a squalene-based nanoemulsion (NE) was loaded with resiquimod, a TLR7/8 agonist for therapeutic delivery. R848 NE was developed and characterized for long-term stability. In vitro and in viv...
Main Authors: | Zhongkun Zhang, Jimmy Chun-Tien Kuo, Chi Zhang, Yirui Huang, Zerui Zhou, Robert J. Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/12/2060 |
Similar Items
-
Evaluation of a Lipopolysaccharide and Resiquimod Combination as an Adjuvant with Inactivated Newcastle Disease Virus Vaccine in Chickens
by: Bal Krishan Sharma, et al.
Published: (2022-06-01) -
Liposomal Resiquimod for Enhanced Immunotherapy of Peritoneal Metastases of Colorectal Cancer
by: Griffin Pauli, et al.
Published: (2021-10-01) -
Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment
by: Supreeda Tambunlertchai, et al.
Published: (2022-09-01) -
Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors
by: Clément Anfray, et al.
Published: (2024-01-01) -
Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio in vitro and in vivo
by: Manuel Keppler, et al.
Published: (2023-06-01)